Related Experiment Video
Updated: Aug 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
C-kit as a target in the treatment of acute myelogenous leukemia
1Department of Hematology Medical Oncology, Desk 35, The Cleveland Clinic Lerner College of Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA. advania@ccf.org
Abstract:
Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are currently being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of de novo AMLs and 95% of relapsed AMLs. C-kit mediates proliferation and anti-apoptotic effects in AML. This review will discuss the biology of c-kit in normal and malignant hematopoiesis, and the recent clinical trials targeting c-kit in AML.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

